MILIND JAVLE to Adult
This is a "connection" page, showing publications MILIND JAVLE has written about Adult.
Connection Strength
0.830
-
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. Oncologist. 2022 Oct 01; 27(10):874-883.
Score: 0.035
-
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815.
Score: 0.032
-
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep. 2020 12 16; 10(1):22087.
Score: 0.030
-
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 05 30; 11(1):71.
Score: 0.026
-
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 01 20; 36(3):276-282.
Score: 0.025
-
Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017 07; 22(7):804-810.
Score: 0.024
-
HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015 May 29; 8:58.
Score: 0.021
-
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383.
Score: 0.020
-
Biomarkers of TGF-? signaling pathway and prognosis of pancreatic cancer. PLoS One. 2014; 9(1):e85942.
Score: 0.019
-
Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014 Apr; 45(4):701-8.
Score: 0.019
-
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010 Jul 14; 10:368.
Score: 0.015
-
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer. 2009 Jun 16; 100(12):1842-5.
Score: 0.014
-
Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest. 2009 Feb; 27(2):193-200.
Score: 0.013
-
Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol. 2007 Dec; 14(12):3527-33.
Score: 0.012
-
Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007 Sep-Oct; 27(5B):3465-70.
Score: 0.012
-
Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. Hepatogastroenterology. 2007 Jul-Aug; 54(77):1339-44.
Score: 0.012
-
Cystic pancreatic tumors (CPT): predictors of malignant behavior. J Surg Oncol. 2007 Mar 01; 95(3):221-8.
Score: 0.012
-
Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J. 2007 Mar-Apr; 13(2):119-24.
Score: 0.012
-
Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol. 2006 Nov; 21(11):1744-51.
Score: 0.011
-
Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol. 2006 Jul; 13(7):933-9.
Score: 0.011
-
Gemcitabine and acute myocardial infarction--a case report. Angiology. 2006 May-Jun; 57(3):367-71.
Score: 0.011
-
Primary esophageal lymphoma: case series and review of the literature. Dig Dis Sci. 2006 Jan; 51(1):77-83.
Score: 0.011
-
Management of locoregional stage esophageal cancer: a single center experience. Dis Esophagus. 2006; 19(2):78-83.
Score: 0.011
-
Postoperative computed tomography scan surveillance for patients with stage II and III colorectal cancer: worthy of further study? Am J Clin Oncol. 2005 Feb; 28(1):30-5.
Score: 0.010
-
Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology. 2004 Nov-Dec; 51(60):1653-7.
Score: 0.010
-
Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients? Dis Esophagus. 2004; 17(2):129-35.
Score: 0.009
-
Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev. 2023 10 02; 32(10):1338-1347.
Score: 0.009
-
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. Hepatology. 2023 09 01; 78(3):758-770.
Score: 0.009
-
The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022 02; 75(2):297-308.
Score: 0.008
-
Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precis Oncol. 2021 08; 5.
Score: 0.008
-
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050.
Score: 0.008
-
Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813.
Score: 0.008
-
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 02; 39(1):182-192.
Score: 0.007
-
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839.
Score: 0.007
-
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 09; 21(9):1234-1243.
Score: 0.007
-
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002.
Score: 0.007
-
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.
Score: 0.007
-
Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs. 2020 12; 38(6):1763-1773.
Score: 0.007
-
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer. 2020 02; 8(1).
Score: 0.007
-
Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res. 2020 03 15; 26(6):1385-1394.
Score: 0.007
-
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
Score: 0.007
-
Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med. 2018 11 06; 16(1):300.
Score: 0.007
-
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
Score: 0.007
-
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):619-627.
Score: 0.007
-
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer. 2018 10 01; 124(19):3890-3899.
Score: 0.007
-
Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
Score: 0.006
-
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291.
Score: 0.006
-
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs. 2018 12; 36(6):1037-1043.
Score: 0.006
-
Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601.
Score: 0.006
-
Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018 05; 3(5):337-348.
Score: 0.006
-
Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension. Oncologist. 2018 06; 23(6):712-718.
Score: 0.006
-
Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist. 2018 03; 23(3):277-e26.
Score: 0.006
-
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
Score: 0.006
-
Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799.
Score: 0.006
-
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.
Score: 0.006
-
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br J Cancer. 2017 Mar 14; 116(6):697-702.
Score: 0.006
-
Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. Br J Surg. 2017 Feb; 104(3):267-277.
Score: 0.006
-
Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer. 2017 04 15; 123(8):1354-1362.
Score: 0.006
-
Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer. 2017 May 15; 123(6):1011-1017.
Score: 0.006
-
Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):323-332.
Score: 0.006
-
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 2016 12 01; 122(23):3657-3666.
Score: 0.006
-
Biologic mesh spacer placement facilitates safe delivery of dose-intense radiation therapy: A novel treatment option for unresectable liver tumors. Eur J Surg Oncol. 2016 Oct; 42(10):1591-6.
Score: 0.006
-
Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016 09 01; 122(17):2671-9.
Score: 0.006
-
Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Additional Options for an Orphan Cancer. J Mol Diagn. 2016 05; 18(3):388-394.
Score: 0.005
-
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
Score: 0.005
-
Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):755-65.
Score: 0.005
-
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016 Jan 20; 34(3):219-26.
Score: 0.005
-
Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol. 2016 May; 69(5):403-8.
Score: 0.005
-
The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1221-8.
Score: 0.005
-
Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer. Diagn Pathol. 2015 Aug 21; 10:148.
Score: 0.005
-
Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2015 Sep; 76(3):489-498.
Score: 0.005
-
Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg. 2015 Apr; 261(4):733-9.
Score: 0.005
-
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol. 2015 Jul; 54(7):971-8.
Score: 0.005
-
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
Score: 0.005
-
Upper esophageal spasm in systemic sclerosis. J Assoc Physicians India. 1993 Aug; 41(8):545-6.
Score: 0.005
-
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83.
Score: 0.004
-
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.
Score: 0.004
-
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc. 2012 Feb; 75(2):332-8.
Score: 0.004
-
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011 Aug 01; 29(22):3037-43.
Score: 0.004
-
Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. Ann Surg Oncol. 2011 Dec; 18(13):3615-22.
Score: 0.004
-
Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci. 2011 May; 56(5):1557-64.
Score: 0.004
-
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010 Apr 15; 116(8):1938-46.
Score: 0.004
-
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. Oncology. 2010; 78(2):125-9.
Score: 0.004
-
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
Score: 0.004
-
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res. 2010 Jan 01; 16(1):320-9.
Score: 0.004
-
Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol. 2009 Nov 18; 4:55.
Score: 0.004
-
High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2009 Oct; 29(10):4127-30.
Score: 0.004
-
Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76(4):1193-8.
Score: 0.003
-
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol. 2009 Apr; 63(5):851-7.
Score: 0.003
-
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol. 2007 Aug; 30(4):350-7.
Score: 0.003
-
CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg. 2007 Apr; 11(4):445-51.
Score: 0.003
-
COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Ann Surg Oncol. 2007 Feb; 14(2):752-8.
Score: 0.003
-
Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Ann Surg Oncol. 2007 Feb; 14(2):833-40.
Score: 0.003
-
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol. 2007 Apr; 59(5):581-7.
Score: 0.003
-
Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. Am J Clin Oncol. 2005 Dec; 28(6):560-4.
Score: 0.003
-
Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res. 2005 Nov 01; 11(21):7794-9.
Score: 0.003
-
Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Clin Cancer Res. 2005 Aug 15; 11(16):5942-9.
Score: 0.003
-
Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma. Int J Gastrointest Cancer. 2005; 35(3):171-7.
Score: 0.003
-
Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer. 2004 Dec 15; 101(12):2722-6.
Score: 0.003
-
Carcinoma of the esophagus with mixed basaloid squamous and glandular differentiation: a distinct histological presentation. Int J Gastrointest Cancer. 2003; 34(2-3):139-42.
Score: 0.002